Investor Presentaiton

Ostomy Care grew 6% in Q2 with solid contribution from all regions ex. China. China detracted from growth due to COVID-19, as expected 9 13. 10 Ostomy Care performance 8 5 2,253 2,274 2,109 2,160 2,204 III • • Q2 2022/23 highlights All regions contributed to growth ex. China Solid growth contribution from Europe, driven by the UK and Germany Solid momentum in the US with double-digit growth and continued advancement of our competitive position. The renewal of Coloplast's group purchasing agreement with Premier Inc. took effect on April 1 Emerging markets ex. China continued the good momentum, led by LATAM Sales in China declined in Q2, as expected, negatively impacted by COVID-19. Towards the end of Q2, hospital access in China significantly improved and approached pre-COVID levels, positively impacting procedural volumes and inflow of new patients From a product perspective, the SenSuraⓇ Mio portfolio, and in particular SenSuraⓇ Mio Convex, was the main growth contributor, followed by the BravaⓇ range of supporting products 6 Q2 21/22 Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23 Revenues (DKKm) Organic growth (%) Reported growth (%) Coloplast

View entire presentation